---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-077636"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:21:53.952115+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data

## Summary
- Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.
- Phase 2 DAVIO 2 data: favorable safety, BCVA nearly identical to aflibercept at 12 months post single injection.
- After single DURAVYU dose, ~50% of eyes were supplement-free at 12 months vs 22% for aflibercept control.
- Phase 2 VERONA trial in DME fully enrolled with 27 patients; no drug-related SAEs reported.
- First patient dosing in Phase 3 LUGANO expected 2H 2024; FDA alignment on non-inferiority design with redosing.

## SEC filing metadata
- accession: 0000950170-24-077636
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/0000950170-24-077636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/eypt-20240626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-077636
- JSON: https://secwatch.observer/filing/0000950170-24-077636.json
- Plain text: https://secwatch.observer/filing/0000950170-24-077636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.